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Abstract
Aim: This study aims to explore if any correlation exists between islets 
autoantibody profile at diagnosis in children and adolescents with type 1 
diabetes and subsequent development of Hashimoto’s thyroiditis and coeliac 
disease. 
Materials and Methods: In this multicentre retrospective cohort study 
conducted in three hospitals, for children below 18 years of age diagnosed 
with Type 1 Diabetes (T1D) over a ten-year period between 1 January 2009 
and 31 December 2018, electronic Medical Records (DMR) were looked at and 
analysed by using SPSS V24.0, for several data variables such as antibody 
profile (type and number of three antibodies-GAD, IAA and ZnTr8 present and 
their titres), demographical characteristics (BMI, gender, age of onset), severity 
of disease at presentation (DKA vs non-DKA and HbA1c value) and subsequent 
development of Hashimoto’s Thyroiditis (HT) and Coeliac Disease (CD).
Results: Out of 218 children (male = 112, female = 103) tested during this 
study period, IAA was the most prevalent antibody found which was positive in 
90 (41%) cases followed by GAD in 83(38%) and ZnTr8 in 34 (16%) children. 
Median age of onset of T1D was 7.709 years (range 1-17 years) and the 
mean HbA1c at presentation was 8.8% (range 5.5% - 14.6%). HT and CD 
were identified in 31 (12.8%) and 14 (5.8%) cases respectively in this cohort. 
Independent samples t-tests could not identify any significant difference in the 
GAD, IAA and ZnTr8 antibody levels for the children with or without HT{(M = 
148.16, SD = 507.9) and (M = 117.6, SD = 402.2); t (103) = 0.275, p = 0.784 in 
GAD}, {(M = 514.46, SD = 1360.7) and (M = 316.86, SD = 972.02); t (99) = 0.697, 
p = 0.487) in IAA}, {(M = 309.63, SD = 397.76) and (M = 383.26, SD = 462.70) ; t 
(32) = 0.385, p = 0.703) in ZnTr8}. Likewise, there has not been any statistically 
significant difference for those with or without CD {(M = 57.9, SD = 107.5) and 
(M = 91.21, SD = 326.4); t (93) = 0.335, p = 0.739 in GAD}, {(M = 22.41, SD = 
18.0) and (M = 420.87, SD = 1140.2); t (90) = 1.10, p = 0.274 in IAA}. One-way 
ANOVA {F (2) = .970, p = 0.382} could not identify any correlation between 
the number of antibodies present at diagnosis and subsequent development 
of HT. There was, however, a statistically significant difference recognised, as 
determined by a one-way ANOVA {F (2,112) = 3.305, p = < .05} for the number 
of antibodies present and development of CD. Post hoc comparisons using the 
Tukey test showed children presenting with all 3 antibodies were 3.87 times 
more likely to develop CD(p = 0.036). 
Conclusion: IAA was the most prevalent islets autoantibody found in this 
study, followed by GAD and ZnTr8. All three antibodies were positive in 13% 
cases. Although, GAD, IAA and ZnTr8 antibody titres at diagnosis are not 
predictive of subsequent development of HT and CD, the number of antibodies 
present influences the future risk of CD but not for HT. Presence of all the three 
antibodies nearly quadruples the possibility of subsequent development of CD. 
As HLA typing is not a predictor of development of CD in children with T1D, this 
finding can influence the frequency of serology testing. 
Keywords: T1D: Type 1 Diabetes mellitus; IAs: Islets Autoantibodies; 
GADA: Glutamic Acid Decarboxylase Antibody; IAA: Insulin Autoantibody; IA-
2A: Insulinoma Antigen-2 Antibody; ZnTr8A: Zinc Transporter 8 Antibody; HT: 
Hashimoto’s Thyroiditis; CD: Coeliac Disease
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Introduction
Type 1 Diabetes mellitus (T1D) is an autoimmune disease 
characterized by loss of insulin producing beta cells and, therefore, 
life-long requirement of exogenous insulin for survival. This is one 
of the most common chronic medical condition in children and 
young adults equally affecting both males and females with classical 
symptoms of polyuria, polydipsia and weight loss despite polyphagia 
[1]. Although, T1D affects nearly half a million population worldwide, 
fortunately, the overall incidence has not been rising over the last 15 
years in Australia [2]. In individuals with a genetic predisposition 
(polymorphism in HLA locus and in gene producing insulin and 
PTPN22), an unidentified trigger initiates an abnormal immune 
response and the development of Islet Autoantibodies (IAs) directed 
against proteins such as insulin, glutamic acid decarboxylase, islet 
antigen 2, and zinc transporter 8, found on secretory granules within 
pancreatic beta cells [3]. T1D is also associated with other autoimmune 
diseases such as Hashimoto’s Thyroiditis (HT), Coeliac Disease 
(CD), Addison’s disease and rheumatoid arthritis. Development of 
IAs occurs before clinical diagnosis of T1D and many have multiple 
IAs present at diagnosis. Similarly, antibodies suggestive of other 
comorbid autoimmune conditions such as anti-TPO (for HT) and 
TTG, AGA, EMA (for CD) are already present in some cases of T1D 
at diagnosis. CD is associated withT1D in 4% - 9% of all cases and 
vice versa and both are two genetic disorders involving similar genes 
(HLA DQ2 and DQ8). CD usually develops within 10 years of T1D 
onset [4]. HT occurs in approximately 3-8% of the children and 
young adults with T1D, with an incidence between 0.3 and 1.1 in 100 
children and teenagers with T1D per year [5]. In addition to the index 
case the family members have higher rate of development of HT and 
CD compared to general population. The presence of HT and CD 
in children with T1D may have an overall impact on the glycaemic 
control, health-related quality of life of the child and on the family 
as a whole. Unfortunately, there has not been any robust clinical or 
laboratory tool available to predict the future occurrence of HT and 
CD in children with T1D. Regular surveillance with the laboratory 
testing of thyroid function test (TSH, T4), anti-TPO antibody, anti-
TTG and AGA etc in the asymptomatic phase is currently practiced 
for the timely identification of these comorbidities [6].
Islets Autoantibodies
Autoantibodies against Glutamic Acid Decarboxylase (GAD), 
insulinoma antigen-2 (IA-2A), insulin (IAA) and the most recently 
Zinc transporter 8 (ZnT8A) are commonly used biomarkers for 
T1D in both children and adults. Islet antibodies (IAs), measured by 
sensitive and specific liquid phase assays, are the key parameters of the 
autoimmune response monitored for diagnostics or prognostics in 
patients with T1D [7]. Islet Autoantibody Standardization Program, 
previously known as DASP, supervised by the Immunology of 
Diabetes Society, organized by the Trial Net Islet Cell Autoantibody 
Core Laboratory at the Department of Pathology of the University 
of Florida, USA controls the standard of ICA measurements. 
IA-2 and Zn T8 proteins are found on the membrane of Secretory 
Granules (SG), in addition to insulin contained within, while GAD 
65 is found on the cytoplasmic site of Synaptic-Like Micro-Vesicles 
(SLMV). GAD is highly expressed in β cells and in a minority of 
α cells. GAD antibody is often present in the absence of diabetes 
such as in Autoimmune Polyglandular Syndrome (APS). IA-2 is a 
receptor type Protein Tyrosine Phosphatase (PTP) which is intrinsic 
to the membrane of SG responsible to influence insulin secretion, 
SG biogenesis and homeostasis and β-cell expansion. Insulin in the 
human is expressed almost exclusively in pancreatic beta cells. IAA 
have also been described in other autoimmune diseases like APS and 
Stiff-person syndrome. In β cells the uptake of zinc into secretory 
granules is mainly mediated by zinc transporter 8 (ZnT8) [8]. ZnT8 
transporter is essential for the formation of insulin crystals in beta 
cells, contributing to the packaging efficiency of stored insulin [9].
Seroconversions of Islet Autoantibodies
Siblings of the index case of T1D are at risk of development of 
not only T1D but other associated comorbidities like HT and CD. 
Seroconversions occur very rarely before the age of 6 months in these 
at-risk children, and the peak of incidence of seroconversion takes place 
between 9 and 24 months of age [10]. The rate of seroconversion at 9 
and 24 months were 18.5 and 21 new cases per 1000 high risk children 
per year, respectively, compared to 9.1, 5.1, and 6.9 seroconversions 
per 1000 high-risk children years at 5, 11, and 14 years of age [11]. 
The incidence of IAA at seroconversion peaked earlier and was 
significantly higher than that of GADA, IA-2A, and ZnT8A [11]. 
Multiple islet autoantibodies, when present, tends to occur in the 
younger age group. In around 70% of the cases, from single antibody 
at presentation to multiple antibody seroconversion happens in 2 
years’ time [12]. IAs show a predominance of immunoglobulins 
mostly of the IgG1 class for GADA, IA-2A, and in addition also of the 
IgG3 and IgG4 class for IAA, already at seroconversion as opposed 
to the sequential appearance of immunoglobulin M to IgG of a 
classical de novo immunization process [13]. Frequency prevalence 
of autoantibody positivity at onset of disease range in decreasing 
order was seen in >80% for GADA, ≥70% for IA-2A, ≥65% for 
ZnT8A, and >50% for IAA in a large population-based study [14]. In 
another study of 750 children with T1D living in Taiwan, 66.3% had 
GADA, 65.3% IA2A, 35.7% IAA, and 17.2% had no autoantibodies 
[15]. Those children with higher IAA or IA-2A antibody have a 
two to fourfold increase in risk of developing T1D within 10 years 
[16]. Female patients had significantly higher prevalence of GADA 
compared with male patients (72.3% vs. 59.7%, P = 0.00027) [15].
Materials and Methods
Three IAs (GADA, IAA and ZnTr8A) were tested among the 
children below 18 years diagnosed with T1D since January 2009 till 
31st of December, over a ten-year period across the state of Tasmania 
in three different hospitals. In this multicentre retrospective cohort 
study electronic Medical Records (DMR) were looked at and collected 
data were analysed by using SPSS V24.0. Throughout the sites three 
IAs were tested and IA-2A was not included in the panel. Not every 
child had been tested for all three antibodies over. Antibody types, 
titres and number of antibody’s present in each individual were 
looked at. Demographical characteristics (BMI, gender, age of onset), 
severity of disease at presentation (Diabetic Ketoacidosis vs non-
DKA and HbA1c value) and subsequent development of HT and CD 
were explored to determine if the IAs profile based on type, number 
and the titres at diagnoses had any predictive correlation. HT was 
confirmed when the TSH level was higher than 10 m U/L in the 
presence of either anti-TPO or anti-thyroglobulin antibody who were 
being treated with thyroxine. Presence of tissue transglutaminase 
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autoantibodies (TTG antibody), IgA and IgG antibodies to gliadin 
(AGA-IgA, AGA-IgG) were confirmed with the endoscopy and 
intestinal biopsy prior to the diagnosis of CD. Only confirmed cases 
of HT and CD were considered in this study. Ethics approval was 
obtained from the Tasmanian Health and Medical Research Ethics 
Committee (Ref: H0016509).
Results
We identified that 242 participants were eligible for this study. 
However, there was incomplete data for 24 cases, which were then 
excluded reducing the participant numbers to 218. The demographics 
for this population are described in (Table 1).
An independent samples t-test was performed to compare 
islets antibody levels in females and males (Table 2). There was no 
significant difference in the GAD antibody levels for females (M = 
151.1, SD = 446.7) and males (M = 93.54, SD = 359.1); t (115) = 0.773, 
p = 0.441. Similarly, there was no significant difference in the IAA 
antibody levels for females (M = 315.4, SD = 961.4) and males (M 
= 351.26, SD = 1018.1). There was no significant difference in the 
ZNTr8 antibody levels for females (M = 414.68, SD = 513.5) and 
males (M = 363.24, SD = 513.5).
A Pearson’s correlation coefficient was performed to assess the 
relationship between IAs and age of onset of disease. There was 
no significant correlation between GAD antibody levels and age 
of onset (r = -.06, n = 64, p = .638). Also, there was no significant 
correlation between IAA antibody levels and age of onset (r = .088, n 
= 68, p = .475). There was, however, a weak, positive, non-significant 
correlation found between ZnTr8 antibody levels and age of onset (r 
= .142, n = 23, p = .518) ) (Figure 1). 
From a total of 218 cases where antibody levels were measured in 
120 of these, 13% of patients presented with a positive result for all 
three antibodies- GAD, IAA and ZnTr8, 53% of patients presented 
with a positive for 2 antibodies and 33% of patients presented with 
a positive result for one antibody (Figure 1). GAD-IAA has been the 
most frequent combination when two IAs are positive at diagnosis 
(Figure 2).
The antibody fractions are presented in (Figure 2), highlighting 
the difference in numbers between patients who presented with 
normal range GAD, IAA and ZnTr8 antibody levels and those with 
increased antibody levels. 18% presented with a normal range GAD 
antibody level when tested whereas 15% presented with a normal 
range IAA antibody level. When tested for ZnTr8, only 13% presented 
with a normal range ZnTr8 antibody level. It is noted that towards the 
late years there has been a positive trend to include the ZnTr8 in the 
panel to test for T1D at diagnosis.
Independent samples t-tests were performed to compare IAs 
in those with or without HT and also for those with or without CD 
(Table 3). There was no significant difference in the GAD antibody 
levels for children with HT (M = 148.16, SD = 507.9) vs for those with 
normal thyroid function (M = 117.6, SD = 402.2); t (103) = 0.275, p = 
0.784. Similarly, no significant difference found in the IAA antibody 
levels for those with HT (M = 514.46, SD = 1360.7) and without HT 
(M = 316.86, SD = 972.02); t (99) = 0.697, p = 0.487). Also, there 
was no significant difference in the ZnTr8 antibody levels for children 
with hypothyroidism (M = 309.63, SD = 397.76) and euthyroid 
participants (M = 383.26, SD = 462.70); t (32) = 0.385, p = 0.703).
There was no significant difference in the GAD antibody levels for 
Variable
Total Gender
Male
Female
Not specified
N = 218
n = 113
n = 103
n = 2
Age at onset
M  = 7.709 years 
(Range 1-17 years)
HbA1C at presentation
M  = 8.8% 
(Range 5.5% -14.6%)
Initial Serological 
Investigations
GAD positive
IAA Positive
ZnTr8Positive
n = 83 (117)
n = 90 (114)
n = 34 (42)
Reference Range > 1.45
Reference Range > 1.0
Reference Range
Associated Co-morbidities
Hashimoto’s Thyroiditis
Coeliac Disease
n = 31 (12.8%)
n = 14 (5.8%)
Table 1: Demographics of participants.
Gender N GAD Mean p N IAA Mean p N ZnTr8 Mean p
Female
Male
38
45
210.7
86.3
0.195
41
49
392.4
444.4
0.822
15
19
525.1
439.7
0.615
Table 2: Islet Autoantibody and Gender.
Auto-antibody    N GAD Mean    p    N   IAA Mean     p           N    ZnTr8 Mean p
Thyroid Function Test
Positive
Negative
17  
88  
148.16
117.6
0.784
18
85
514.46
316.86
0.487
7
27
309.63
383.26 0.497
Coeliac Disease
Present
Absent
11 
84     
57.9
91.2
0.739
10
82
22.41
420.87
0.274
0
26 301.94 **
Table 3:  Autoantibody and Serological Investigations.
Figure 1: Number of cases presenting with 1, 2 or 3 positive antibody level 
results.
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those with confirmed CD (M = 57.9, SD = 107.5) and those without 
CD (M = 91.21, SD = 326.4); t (93) = 0.335, p = 0.739. There was no 
significant difference in the IAA antibody levels for positive coeliac 
participants (M = 22.41, SD = 18.0) and negative participants (M = 
420.87, SD = 1140.2); t (90) = 1.10, p = 0.274. The ZnTr8 antibody 
profile was unable to be determined as there were insufficient 
participants. The number of cases in each antibody category are 
shown in (Figure 1). There were no statistically significant differences 
between group means as determined by one-way ANOVA (F (2) = 
.970, p = 0.382) for number of antibodies present at time of diagnosis 
and HT. There was, however, a statistically significant difference 
identified between groups as determined by a one-way ANOVA (F 
(2,112) = 3.305, p = < .05) for the number of antibodies present at 
the time of diagnosis and the presence of CD. Post hoc comparisons 
using the Tukey test showed that there was a significant difference 
between 1 positive antibody and 3 positive antibodies (p = 0.036) with 
patients presenting with 3 positive antibodies are 3.87 times more 
likely to have CD than those presenting with only 1 positive antibody. 
Discussion
At presentation, it is a traditional clinical practice to test for the 
islet autoantibody profile, both the types of antibody and the titre, to 
confirm the diagnosis of T1D. Although, the IAs can be negative in 
cases of T1D, it raises the suspicion of Maturity Onset Diabetes of 
Young (MODY) which is not an autoimmune condition. Screening 
for IAs for at risk children, such as for parents and sibling, is currently 
practiced in research settings. The benefits of screening for IAs in 
this group include identifying the children who are likely to develop 
T1D, decreasing the incidence of Diabetic Ketoacidosis (DKA) at 
presentation, initiating insulin therapy sooner in the disease process 
with the aim to delay or prevent progression [17]. The utility the 
IA testing for the index cases for any other clinical information is 
quite limited. The presence of islets autoantibodies at diagnosis did 
not predict micro vascular complication in a large study [18]. T1D 
usually has a preclinical symptomless phase identified by circulating 
IAs, but the rate of progression to diabetes remains uncertain. In a 
multi-centre study, the progression to T1D at 10-year follow-up 
after IA seroconversion was seen in 69.7% (95% CI, 65.1%-74.3%) 
cases when multiple IAs were present compared to 14.5% (95% 
CI, 10.3%-18.7%) of children with a single IA present [19]. Risk of 
diabetes in children who had no IAs was negligible 0.4% (95% CI, 
0.2%-0.6%). Progression to T1D in the children with multiple IAs 
was faster for children who had islet autoantibody seroconversion 
younger than age 3 years (hazard ratio [HR], 1.65 [95% CI, 1.30-2.09; 
P < .001. Although the appearance of autoantibodies does not usually 
follow any distinct pattern, the presence of multiple autoantibodies 
in less than 3 years old has the highest positive predictive value for 
development of T1D [20,21]. Similar trend for CD is also seen in our 
study, the presence of multiple IAs has nearly 4 times higher incidence 
for CD in children with T1D than with single IA. The progression of 
IAs and T1D differs among races/ethnicities in at-risk individuals, 
which is lower in Hispanic compared with non-Hispanic White at-
risk individuals, however, no gender preference identified. Younger 
age, presence of multiple antibodies and certain race increase the 
possibility of development of T1D in at risk individual, whether this 
is also applicable to other comorbidities that remains to be answered. 
What factors predict the possibility of future development of HT and 
CD is the larger question.
In this article we explored whether specific antibody profile have 
any predictive correlation with the subsequent development of CD 
and HT. Antibody levels were found not to be useful in this regard. 
The number of antibodies, however, seems to be positively correlated 
with the future occurrence of CD, but not with HT. Presence of all 
three IAs increased the probability nearly four times the likelihood of 
CD than with single antibody positivity. In our cohort 13% children 
with T1D did have all three antibodies positive. Most of the children 
and adolescents in this study had two antibodies positive in various 
combinations, seen in 53% cases, followed by 33% of cases where 
only one antibody was positive. The commonest combinations were 
GAD-IAA (78%), IAA-ZnTr8 (13%), followed by GAD-ZnTr8 seen 
in 10%. Nearly 13-18% of cases antibodies were negative when tested 
for. Those who are negative or positive with single antibody the 
future likelihood of development of CD is minimal. There has been a 
clear association between specific HLA haplotypes and development 
of IAs. In particular, GADA are associated more strongly with the 
HLA DR3-DQ2 haplotype, while IAA and IA-2A are more associated 
with the HLA DR4-DQ8 haplotype [11]. The frequency of Coeliac 
Disease (CD)-specific HLA genotypes, HLA-DQ2, HLA-DQ8 or 
both is positive in the vast majority (>80%) of patients with T1D and 
therefore, screening for coeliac-specific HLA genotypes as a first-
line test is not a suitable method to predict likely development of 
CD in T1D. Regular screening for coeliac-specific antibodies in T1D 
remains standard of current clinical practice [22].
As an autoimmune disease, T1D can be associated with other 
autoimmune disorders such as autoimmune thyroid disease, coeliac 
disease, and Addison’s disease. The presence of autoantibodies was 
evaluated with special regard to the control of diabetes and to the 
clinical status of the patient. Autoantigens of the small intestine 
- Tissue Transglutaminase Autoantibodies (ATTG), IgA and IgG 
antibodies to gliadin (AGA-IgA, AGA-IgG) were evaluated by 
ELISA. The screening of autoantibodies in type 1 diabetic patients 
could reveal subclinical cases of AITD or coeliac disease. Subclinical 
forms of these disorders have no influence on diabetes control [5]. 
In this elevated TPOA and EMA levels at diagnosis of T1D predict 
the development of HT and CD, respectively. In children with 
negative antibody titres at diagnosis, screening at 2-year intervals is 
recommended [18].
Limitations 
1. Inconsistency in pathological tests requested during this 10-
Figure 2: Numbers of cases by antibody level.
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year study period. Not all of them have been tested for all the three 
antibodies. 
2. Another limitation is the availability of pathology data – some 
of the cases may have had their antibody levels done but the data was 
not available though he DMR or through the pathology lab (e.g. may 
have been done interstate or through a private provider).
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